In The News Posted January 8, 2020 Share Posted January 8, 2020 TEL AVIV, Israel, Jan. 8, 2020 /PRNewswire/ -- Cellect Biotechnology Ltd. (Nasdaq: APOP) ("Cellect" or the "Company"), a developer of innovative technology which enables the functional selection of stem cells, today announced it has entered into a securities purchase agreement with... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.